AB-452
AB-452, a Dihydroquinolizinone (DHQ) analogue, is a potent and orally active HBV RNA destabilizer. AB-452 inhibits PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model.
For research use only. We do not sell to patients.
- CAS No.: 2226178-35-2
- Formula: C21H26N2O6
- Molecular Weight:402.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | EC50 |
3 nM
Compound: (S)-20; AB-452
|
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBeAg level measured after 16 days by ELISA
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBeAg level measured after 16 days by ELISA
|
[PMID: 38190324] |
| Hepatocyte | EC50 |
3 nM
Compound: (S)-20; AB-452
|
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBsAg level measured after 16 days by ELISA
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBsAg level measured after 16 days by ELISA
|
[PMID: 38190324] |
| Hepatocyte | EC50 |
3 nM
Compound: (S)-20; AB-452
|
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBV DNA level measured after 16 days by ELISA
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBV DNA level measured after 16 days by ELISA
|
[PMID: 38190324] |
| HepG2 2.2.15 | CC50 |
>50 μM
Compound: (S)-20; AB-452
|
Cytotoxicity against human HepG2.2.15 cells by Cell-titer Glo luminescent assay
Cytotoxicity against human HepG2.2.15 cells by Cell-titer Glo luminescent assay
|
[PMID: 38190324] |
| HepG2 2.2.15 | EC50 |
0.001 μM
Compound: (S)-20; AB-452
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay
|
[PMID: 38190324] |
Chemical Information
-
CAS No. 2226178-35-2
-
Molecular Weight 402.44
-
Formula C21H26N2O6
-
SMILES
CC([C@H]1N2C(C3=NC(OC)=C(OCCCOC)C=C3C1)=CC(C(C(O)=O)=C2)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)